Immunotherapy is a cancer treatment that enhances the immune system's ability to fight cancer. Immunotherapy is preferable than the old technique as it helps treat a wider range of cancer, provide long-term cancer protection, and has less side effects. Immunotherapy drugs are used to treat different types of cancers. They work by activating the immune system to mobilize the target, directing the immune system toward cancer-specific targets, and triggering a response capable of destroying cancer cells. Immunotherapy drugs enable immune system to recognize and target cancer cells, making it a universal answer to cancer, and thus, there is an increasing demand for immunotherapy drugs worldwide.
High prevalence of cancer, increasing adoption of immunotherapy drugs, rise in demand for monoclonal antibodies and biosimilars, and frequent approvals of novel drugs are some major factors expected to drive growth of the global immunotherapy drugs market during the forecast period. For instance, immunotherapy is a class of cancer treatments that trigger the immune system to fight cancer cells, and thus, has led to an increase in the use of immunotherapy or immunotherapy drugs around the world.
In March 2022, the U.S. Food and Drug Administration (FDA) approved a novel therapy for patients with metastatic or inoperable melanoma, an aggressive type of skin cancer. Moreover, in May 2022, FDA expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania’s (Penn’s) Abramson Cancer Center, this time for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. It remains the only CAR-T cell therapy approved for both adult and pediatric patients.
Key features of the study: